Hematology

Latest News

DLBCL | Image: Atlas of Haematological Cytology
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

July 16th 2025

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

There was significant variability in test frequency and detection rates among patients with AML and MDS. | Image credit: Saiful52-stock.adobe.com
Gaps in Molecular Testing Rates, Targeted Treatment Persist in MDS, AML

July 11th 2025

The findings have potential implications for treatment selection in CLL/SLL, particularly in patients at elevated risk for infectious complications. | Image credit: Eleni - stock.adobe.com
Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL

July 7th 2025

Artwork of community health care with a giant stethoscope and medicine bag | Image credit: TarikVision - stock.adobe.com.
Academic-Community Partnerships Bringing Cancer Care to Patients

July 5th 2025

Clinical trial graphic | Image credit: photon_photo - stock.adobe.com
Comparative Analysis Suggests Zanubrutinib as Most Effective cBTKi in R/R CLL

July 5th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

All of the panelists for this series
January 6th 2021

Importance of MRD Negativity in Changing Relapse Patterns

A discussion on the importance of MRD (minimum residual disease) negativity in changing relapse patterns for patients with multiple myeloma.
Robert K. Massie, Jr, PhD, MA, Society for Progress
January 5th 2021

Dr Robert Massie: Untreated Pooled Plasma Enabled Unchecked Virus Transmission

Decades ago, companies refused to heat-treat their blood products, which resulted in pooled plasma, among others, enabling many viruses to be transmitted, noted Robert K. Massie Jr, PhD, MA, of the Society for Progress.
All of the panelists for this series
December 30th 2020

R/R Multiple Myeloma Rationale for Decreased Response

Key opinion leaders discuss why patients with multiple myeloma experience increasingly decreased response to therapy over time.
Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MM
December 30th 2020

Metabolic Biomarkers Could Predict Prognosis, Treatment Outcomes in MM

Jared Kaltwasser
New research shows metabolic biomarkers could be meaningful tools for predicting treatment outcomes in patients, based on a comparison of biomarkers, clinical characteristics, and therapeutic efficacy.
Top 5 Most-Read Hematology Articles for 2020
December 28th 2020

Top 5 Most-Read Hematology Articles for 2020

Mary Caffrey
Gene-editing therapy in sickle cell disease and advances in multiple myeloma dominated hematology news in 2020.
X-ray
December 23rd 2020

Fractures, Other Skeletal Issues Lead to High Postdischarge Costs in Patients With MM, Bone Metastases

Jared Kaltwasser
Most patients with bone metastases or multiple myeloma (MM) who are hospitalized with skeletal-related events require lengthy and costly follow-up care after they are discharged.
Madduri
December 21st 2020

Rolling Submission Begins for BLA on Cilta-Cel in R/R Multiple Myeloma

Mary Caffrey
Results presented earlier this month at ASH showed a 97% overall response rate, and progression-free survival had not been reached.
Multiple Myeloma Therapy on Cusp of New Era, but Much Is Left to Prove, Review Says
December 17th 2020

Multiple Myeloma Therapy on Cusp of New Era, but Much Is Left to Prove, Review Says

Jared Kaltwasser
Physicians will soon have a more complex set of options when treating patients with multiple myeloma (MM), but the authors of a new review article argued clinicians will need to take a pragmatic approach.
BCMA-Targeted CAR T-Cell Therapy Effective in MM, but With Caveats, Analysis Finds
December 16th 2020

BCMA-Targeted CAR T-Cell Therapy Effective in MM, but With Caveats, Analysis Finds

Jared Kaltwasser
A new meta-analysis finds high rates of efficacy and high rates of toxicity in multiple myeloma patients treated with B-cell maturation agent (BCMA)-targeted chimeric antigen receptor (CAR)- T cells.
Tumor Lysis Syndrome Risk May Rise With Use of Bortezomib for MM in Men
December 11th 2020

Tumor Lysis Syndrome Risk May Rise With Use of Bortezomib for MM in Men

Jared Kaltwasser
The research raises the possibility that the type of therapy used can increase the risk of tumor lysis syndrome from low to moderate in men with multiple myeloma (MM).
Exploring Biomarker-Based Risk Stratification in Smoldering Multiple Myeloma
December 9th 2020

Exploring Biomarker-Based Risk Stratification in Smoldering Multiple Myeloma

Jared Kaltwasser
The science around risk stratification in patients with smoldering multiple myeloma (SMM) has been evolving over the past 2 decades. A new study validates some, though not all, of the proposed biomarkers.
Study Examines Trends in Mortality Rates of Multiple Myeloma in US Adults
December 4th 2020

Study Examines Trends in Mortality Rates of Multiple Myeloma in US Adults

AJMC Staff
The United States is becoming older, more diverse, and more overweight, and these changes may influence future trends in certain hematological cancers.
Considerations for Designing ePRO Interventions for Patients With RRMM
December 4th 2020

Considerations for Designing ePRO Interventions for Patients With RRMM

Skylar Jeremias
Patients and health care providers evaluated the use of an electronic patient-reported outcome (ePRO) intervention for use in a clinic setting for patients with relapsed or refractory multiple myeloma (RRMM).
Review Examines New Options for Patients With Aplastic Anemia
November 28th 2020

Review Examines New Options for Patients With Aplastic Anemia

AJMC Staff
Severe aplastic anemia used to have few options and mortality was high, but a new class of drugs offers some hope.
Real-World Data Confirm KRd Safety, Efficacy in RRMM
November 26th 2020

Real-World Data Confirm KRd Safety, Efficacy in RRMM

Jared Kaltwasser
New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma.
Selinexor Shows Promise in Combination With Daratumumab, Dexamethasone in RRMM
November 20th 2020

Selinexor Shows Promise in Combination With Daratumumab, Dexamethasone in RRMM

Jared Kaltwasser
The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM).
Hypercalcemia in Multiple Myeloma Leads to Poor Prognosis
November 18th 2020

Hypercalcemia in Multiple Myeloma Leads to Poor Prognosis

Jared Kaltwasser
New research attempts to answer some of the mystery related to the causes and impact of hypercalcemia in patients with newly diagnosed multiple myeloma.
Enhanced CAR T cell
November 12th 2020

Radiation Does Not Disrupt CAR T-Cell Therapy in Patients With MM, Study Finds

Jared Kaltwasser
New research suggests it’s not disruptive to give radiation therapy to patients who are awaiting CAR T-cell therapy for relapsed or refractory multiple myeloma.
Multiple myeloma iPad display
November 10th 2020

Once-Weekly KRd Shows Promise in Newly Diagnosed MM

Jared Kaltwasser
Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally successful.
Circulating Cell-Free DNA Could Be Marker of Progression in Multiple Myeloma
November 6th 2020

Circulating Cell-Free DNA Could Be Marker of Progression in Multiple Myeloma

Jared Kaltwasser
A new study suggests a potential new marker that could be used to track response to therapy and disease progression in patients with multiple myeloma.
Carfilzomib molecule
November 3rd 2020

New Analysis Aims to Characterize Patients With Best Carfilzomib Responses

Jared Kaltwasser
There did not appear to be any particular patient characteristics linked with best responses to carfilzomib in patients with multiple myeloma, with the exception of low serum lactate dehydrogenase.
Multiple myeloma
October 29th 2020

Use of Triplet Therapy Rose in R/R MM as Deaths Declined, Study Finds

Jared Kaltwasser
Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.
Older Patient
October 22nd 2020

Patients With MM Living Longer, but Elderly Still Face Worse Survival

Jared Kaltwasser
New data show that despite major improvements in survival rates in patients with multiple myeloma (MM), older patients with the malignancy have benefited less than younger patients.
Drops in Circulating MicroRNA-451a Could Be Sign of MM Relapse
October 21st 2020

Drops in Circulating MicroRNA-451a Could Be Sign of MM Relapse

Jared Kaltwasser
Investigators may have found a minimally invasive way to predict which patients with multiple myeloma are about to experience a relapse.
Drug cost concept
October 13th 2020

CML Treatment Costs Continue to Rise Despite Availability of Generic Imatinib

Jared Kaltwasser
Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib.
Intestines
October 13th 2020

Colon Perforations in MM, While Rare, Linked With Corticosteroids

Jared Kaltwasser
A new report confirms earlier research that colon perforation in multiple myeloma is associated with corticosteroids, though the exact cause of the apparent link is not known.
Picture of bacteria
October 7th 2020

MM Staging, Severe Anemia Linked With High Infection and Mortality Risk

Jared Kaltwasser
Newly diagnosed patients with multiple myeloma (MM) face a high risk of infection. A new study helps elucidate key risk factors.
MRD Potential in MM Undeniable, Even if Not Ready for Use Yet, Review Says
September 30th 2020

MRD Potential in MM Undeniable, Even if Not Ready for Use Yet, Review Says

Jared Kaltwasser
A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.
Frailty Definitions Too Imprecise in Patients With MM, New Paper Suggests
September 27th 2020

Frailty Definitions Too Imprecise in Patients With MM, New Paper Suggests

Jared Kaltwasser
A subset of patients with multiple myeloma (MM) are not eligible for the most effective therapies, but a new study suggests clinicians may be inaccurately defining that subset.
Medical question image
September 23rd 2020

Review Updates Mechanisms Underlying Proteasome Inhibitor Resistance in MM

Jared Kaltwasser
Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle.
<1
...
5678910111213
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo